• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞色素P450酶的基因多态性:克罗地亚人群中的CYP2C9、CYP2C19、CYP2D6、CYP3A4和CYP3A5

Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.

作者信息

Ganoci Lana, Božina Tamara, Mirošević Skvrce Nikica, Lovrić Mila, Mas Petar, Božina Nada

出版信息

Drug Metab Pers Ther. 2017 Mar 1;32(1):11-21. doi: 10.1515/dmpt-2016-0024.

DOI:10.1515/dmpt-2016-0024
PMID:28272018
Abstract

BACKGROUND

Data on the frequency of pharmacogenetic polymorphisms in the Croatian population are limited. We determined and analyzed frequencies for the most important CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genetic variants in the Croatian population.

METHODS

2637 subjects were included. Genotyping was performed by real-time polymerase chain reaction (PCR) using TaqMan® DME or TaqMan® SNP Genotyping Assays, and by PCR, and PCR-RFLP analysis.

RESULTS

For CYP2C9, allele frequencies of *2 and *3 variant were 14.5% and 7.6%, respectively. Among them, 3.98% of subjects were predicted to be poor metabolizers. For CYP2C19, the most frequent variant alleles were *2 (14.8%), and *17 (23.7%), while 2.4% of subjects were predicted to be poor metabolizers, and 5.39% were homozygous carriers of *17 predicted to be ultrarapid metabolizers (UM). For CYP2D6, the frequencies of tested variant alleles were *3 (2.2%), *4 (17.4%), *5 (1%), *6 (1.1%), and 41 (10.8%). Out of these, 5.59% were predicted to be poor metabolizers, 3.19% were classified as UM while 1.0% were carriers of variant alleles duplications (undefined phenotype). For CYP3A4 allele frequencies of 1B and 22 variants were 1.4% and 2.7%, respectively. Allele frequency of CYP3A53 was 95.5%. Analyzing CYP3A cluster according to the combination of CYP3A422 and CYP3A53 revealed 5.34% of subjects to be poor metabolizers, while 8.66% were classified as extensive metabolizers.

CONCLUSIONS

The frequency of the CYP allelic variants, genotypes, and predicted phenotypes in the Croatian population is in accordance with the other European populations, between the values of published data for Middle European and Mediterranean populations.

摘要

背景

克罗地亚人群中药物遗传多态性频率的数据有限。我们测定并分析了克罗地亚人群中最重要的CYP2C9、CYP2C19、CYP2D6、CYP3A4和CYP3A5基因变体的频率。

方法

纳入2637名受试者。使用TaqMan® DME或TaqMan® SNP基因分型检测试剂盒通过实时聚合酶链反应(PCR)、PCR以及PCR-RFLP分析进行基因分型。

结果

对于CYP2C9,2和3变体的等位基因频率分别为14.5%和7.6%。其中,3.98%的受试者预计为慢代谢者。对于CYP2C19,最常见的变体等位基因为2(14.8%)和17(23.7%),而2.4%的受试者预计为慢代谢者,5.39%为17纯合携带者,预计为超快代谢者(UM)。对于CYP2D6,检测到的变体等位基因频率分别为3(2.2%)、4(17.4%)、5(1%)、6(1.1%)和41(10.8%)。其中,5.59%预计为慢代谢者,3.19%被归类为UM,而1.0%为变体等位基因重复携带者(未明确表型)。对于CYP3A4,1B和22变体的等位基因频率分别为1.4%和2.7%。CYP3A53的等位基因频率为95.5%。根据CYP3A422和CYP3A5*3的组合分析CYP3A簇,发现5.34%的受试者为慢代谢者,而8.66%被归类为广泛代谢者。

结论

克罗地亚人群中CYP等位基因变体、基因型和预测表型的频率与其他欧洲人群一致,介于中欧和地中海人群已发表数据的值之间。

相似文献

1
Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.细胞色素P450酶的基因多态性:克罗地亚人群中的CYP2C9、CYP2C19、CYP2D6、CYP3A4和CYP3A5
Drug Metab Pers Ther. 2017 Mar 1;32(1):11-21. doi: 10.1515/dmpt-2016-0024.
2
Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.克罗地亚人群中细胞色素P450的基因多态性:CYP2C9、CYP2C19和CYP2D6
Croat Med J. 2003 Aug;44(4):425-8.
3
Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.希腊人群中药物代谢酶CYP2D6、CYP2C9、CYP2C19和CYP3A5的基因多态性
Fundam Clin Pharmacol. 2007 Aug;21(4):419-26. doi: 10.1111/j.1472-8206.2007.00510.x.
4
Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.约旦人群中多态细胞色素 P450 基因(CYP1A1、CYP3A4、CYP3A5、CYP2C9 和 CYP2C19)的等位基因和基因型频率。
Mol Biol Rep. 2012 Oct;39(10):9423-33. doi: 10.1007/s11033-012-1807-5. Epub 2012 Jun 22.
5
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.意大利人群中CYP2C9、CYP2C19和CYP2D6的等位基因及基因型频率
Pharmacol Res. 2004 Aug;50(2):195-200. doi: 10.1016/j.phrs.2004.01.004.
6
Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.不丹人群中CYP2C9、CYP2C19、CYP2D6和CYP3A5的药物遗传学相关多态性
Drug Metab Pers Ther. 2019 Dec 18;34(4). doi: 10.1515/dmpt-2019-0020.
7
CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.阿什肯纳兹犹太人群体中CYP2C9、CYP2C19和CYP2D6等位基因频率
Pharmacogenomics. 2007 Jul;8(7):721-30. doi: 10.2217/14622416.8.7.721.
8
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.法罗群岛人群中CYP2D6、CYP2C19、CYP2C9和CYP2C8的多态性
Eur J Clin Pharmacol. 2005 Aug;61(7):491-7. doi: 10.1007/s00228-005-0938-1. Epub 2005 Jul 16.
9
CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.CYP2C9、CYP2C19、CYP2D6 和 CYP3A5 多态性在东南亚和东亚人群中的研究:系统评价。
J Clin Pharm Ther. 2019 Aug;44(4):508-524. doi: 10.1111/jcpt.12835. Epub 2019 Apr 13.
10
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.俄罗斯人群中药物代谢酶CYP2C9、CYP2C19、CYP2D6、CYP1A1、NAT2及P-糖蛋白的多态性
Eur J Clin Pharmacol. 2003 Aug;59(4):303-12. doi: 10.1007/s00228-003-0606-2. Epub 2003 Jul 15.

引用本文的文献

1
Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis.钾离子竞争性酸阻滞剂的临床药代动力学:系统评价与荟萃分析。
Front Pharmacol. 2025 Jul 8;16:1580969. doi: 10.3389/fphar.2025.1580969. eCollection 2025.
2
Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.在未经抗凝治疗的非瓣膜性心房颤动患者中,利伐沙班治疗相关出血事件:一项基于基因角度并随访 INR 的纵向研究。
Medicina (Kaunas). 2024 Oct 18;60(10):1712. doi: 10.3390/medicina60101712.
3
Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach.
厄瓜多尔人群中CYP2C19的基因多态性:一种跨种族研究方法。
Heliyon. 2024 Mar 27;10(7):e28566. doi: 10.1016/j.heliyon.2024.e28566. eCollection 2024 Apr 15.
4
Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol.曲马多治疗儿童中CYP2D6表型分析的瞳孔测量法评估
Pharmaceuticals (Basel). 2023 Aug 30;16(9):1227. doi: 10.3390/ph16091227.
5
Variations in the Frequencies of Polymorphisms in the CYP450s Genes in Eight Major Ethnicities of Iran: A Review of the Human Data.伊朗八个主要民族CYP450基因多态性频率的变化:人类数据综述
J Pers Med. 2022 Nov 5;12(11):1848. doi: 10.3390/jpm12111848.
6
Pharmacogenetic distinction of the Croatian population from the European average.克罗地亚人群与欧洲平均人群的药物遗传学差异。
Croat Med J. 2022 Apr 30;63(2):117-125. doi: 10.3325/cmj.2022.63.117.
7
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes.基于选定药物代谢基因的代谢表型对 EMPAR 研究人群进行评估。
Pharmacogenomics J. 2022 Mar;22(2):136-144. doi: 10.1038/s41397-022-00268-6. Epub 2022 Jan 31.
8
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.SLCO1B1(c.521T>C,rs4149056)和 ABCG2(c.421C>A,rs2231142)基因的功能丧失多态性与瑞舒伐他汀的不良事件相关:一项病例对照研究。
Eur J Clin Pharmacol. 2022 Feb;78(2):227-236. doi: 10.1007/s00228-021-03233-7. Epub 2021 Oct 19.
9
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.群体药物基因组学:种族地理差异及精准公共卫生的机遇更新。
Hum Genet. 2022 Jun;141(6):1113-1136. doi: 10.1007/s00439-021-02385-x. Epub 2021 Oct 15.
10
Prevalence of five pharmacologically most important and allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina.波黑塞族共和国人群中五种药理学上最重要的等位基因变体的流行情况。
Arh Hig Rada Toksikol. 2021 Jun 28;72(3):129-134. doi: 10.2478/aiht-2021-72-3499.